Objectives: Few head-to-head comparisons of cocaine dependence medications exist, and combining data from different randomized controlled trials (RCTs) is fraught with methodological challenges including limited generalizability of the RCT findings. This study applied a novel metaanalytic approach to data of cocaine dependence medications.
There is clearly a need for evidence-based interventions for cocaine use disorders. There are a number of behavioral interventions shown to be effective for treating cocaine use disorders including contingency management (Kampman, 2010) , cognitive-behavioral therapy (Penberthy, Ait-Daoud, Vaughan, & Fanning, 2010) , and therapeutic communities (Vanderwert, Marshall, Nelson, Zeanah, & Fox, 2010) .
However, there are no pharmacological treatments for cocaine use disorder currently approved by the U.S. Food and Drug Administration (National Institute on Drug Abuse, 2016) . A number of potential medications for cocaine use disorders have been examined in randomized clinical trials (RCTs; Castells et al., 2007; de Lima, de Oliveira Soares, Reisser, & Farrell, 2002; Kampman, 2005; Kampman, 2010; Penberthy et al., 2010) . Existing studies targeted several neurobiological agents with putative effects on receptors considered to be involved in cocaine use disorder, such as dopamine, serotonin, gamma-aminobutyric acid, glutamate, and norepinephrine (Shorter, Domingo, & Kosten, 2015) .
The list of medications tried in past studies is long and includes the glutaminergic medication Modafinil (Dackis & O'Brien, 2003) , gamma-aminobutyric acidergic medications such as baclofen, tiagabine, and topiramate (Kampman, 2005) , disulfiram (Carroll et al., 2004) , antidepressants such as desipramine (Arndt, McLellan, Dorozynsky, Woody, & O'Brien, 1994) , and cocaine vaccination that produces antibodies against cocaine (Martell, Mitchell, Poling, Gonsai, & Kosten, 2005) .
Despite some promising evidence of effectiveness in individual RCTs, previous pairwise meta-analyses of medications for cocaine use disorders have failed to produce evidence of overall treatment effectiveness of these medications or to identify clear advantages for one pharmacological agent (Castells et al., 2007; de Lima et al., 2002) . These previous pairwise meta-analyses of medications for cocaine use disorders used a traditional approach of synthesizing study-level data typically obtained from publications. This approach makes it difficult to take into account the differences in the composition of RCT samples and to reliably compare different treatments.
Advances in meta-analytic methodology now make it possible to synthesize individual-level data from different RCTs (Riley, Lambert, & Abo-Zaid, 2010) . Furthermore, the newly introduced method of network meta-analysis, also referred to as mixed treatment meta-analysis or multiple treatment comparison meta-analysis, now makes it possible to estimate comparative effectiveness across multiple interventions that are not evaluated against each other in any one study (Mills, Thorlund, & Ioannidis, 2013) . The synthesis of multiple trials to assess comparative treatment effects is reasonable and transitive as long as different trials were conducted under similar clinical and methodological conditions where characteristics of the participants and the common comparator such as a placebo arm across trials could be assumed homogeneous (Cipriani, Higgins, lGeddes, & Salanti, 2013) .
Another major limitation of past RCTs for treatment of cocaine use disorder is the selective nature of the RCT samples (Sofuoglu, Dudish-Poulsen, Nicodemus, Babb, & Hatsukami, 2000) that limits the external validity, or generalizability of the findings of the RCTs to the target population of individuals with cocaine use disorder in the general population, or to individuals in usual treatment settings.
RCT findings are not directly generalizable to the target populations when there are treatment effect modifiers, and the distributions of the effect modifiers are different between the RCT samples and the target populations. This concern is not limited to cocaine treatment RCTs as there is a growing concern that the findings from RCTs in a number of health fields may not be generalizable to real world settings (Blanco et al., 2008a; Hoertel, Le Strat, Blanco, Lavaud, & Dubertret, 2012; Hoertel, Le Strat, Lavaud, Dubertret, & Limosin, 2013; Hoertel, Santiago, Wang, González-pinto, & Blanco, 2015; Okuda et al., 2010; Rothwell, 2005) . However, the concerns may be amplified with regard to RCTs for treatments of substance use disorders (SUD) because of the stigma associated with such disorders and the specialized setting where treatments are offered may be an added challenge.
There is a growing body of research showing that individuals participating in RCTs are substantially different from the target populations (Blanco et al., 2008b; Humphreys, Weingardt, & Harris, 2007; Humphreys & Weisner, 2000; Okuda et al., 2010) . According to a recent review (Moberg & Humphreys, 2016 ) that synthesized 15 studies examining the impact of SUD trial exclusion criteria on distributions of participants' characteristics, commonly used exclusion criteria in SUD trials would exclude between 64% and 95% of potential participants. Furthermore, Susukida, Crum, Stuart, Ebnesajjad, and Mojtabai (2016) found substantial differences in distributions of characteristics between RCT samples and the target populations by comparing the characteristics of participants in 10 RCTs from the National Institute of Drug Abuse Clinical Trials Network (CTN) and the intended target populations consisting of people who seek treatment for SUD in usual care settings. A more recent study (Susukida, Crum, Ebnesajjad, Stuart, & Mojtabai, 2017) found that the significance of estimated sample treatment effects was different from that of the population effects when the distribution of characteristics of RCT samples was made to resemble the distribution of the target populations by using statistical weighting techniques. Most commonly, positive effects of trials in unweighted RCTs became statistically nonsignificant after weighting. To the best of our knowledge, however, no past studies of SUD treatments have synthesized data from individual RCTs with a view to the generalizability of results for the target population or have attempted to improve generalizability using statistical adjustments.
In this study, we embarked on a pairwise meta-analysis of individual-level data from four RCTs of medications to treat cocaine dependence as well as network meta-analysis of study-level data to compare the effects of these four treatments while incorporating generalizability of the findings of the RCTs to the target populations and adjusting the results to make them more generalizable. Two target populations were selected to investigate and enhance generalizability of the findings from meta-analyses: individuals seeking treatment for cocaine dependence at usual care settings and individuals with cocaine dependence in the general population, regardless of their treatment seeking behavior. Generalizing to these two diverse target samples addresses two distinct policy questions: (a) the efficacy of the treatment for individuals who seek treatment in usual care settings and (b) the efficacy of treatment if treatment is disseminated to the much wider population group who are not currently seeking any treatment but could potentially benefit from it. health problems. We limited the sample to those who met DSM-IV cocaine dependence criteria in the past year (n = 235) for generalizability to the cocaine-dependent individuals in the general population. The sampling weight was taken into account in every statistical analysis in this study because some demographic groups were oversampled in the NSDUH surveys (e.g., young adults).
| Measures
We identified eight comparable variables between the RCTs and the target populations with which to compute statistical weights for generalizing RCT outcomes to the two target populations: sex, raceethnicity, age, educational attainment, employment status, marital status, intravenous drug use, and the number of past treatments for SUD. 
| Statistical analysis
Analyses were conducted in four stages. First, we compared the eight characteristics noted above between the RCT samples and the target populations. Pearson's chi-squared tests were conducted to examine if there were significant differences in the distributions of the eight variables between the RCT samples and the target populations. As the TEDS-A includes a significant amount of missing data (12.7%), we used multiple imputation with the STATA ice command (version 13; Royston, 2004) and created 50 imputed data sets. The percentage of missing observations in each RCT and target populations is presented in Table A1 . There were no missing data in the NSDUH sample.
Second, to generalize the results from the RCTs to the target populations, we used a weighting-based method, which weights RCT samples to resemble the target populations (Cole & Stuart, 2010; Stuart, Bradshaw, & Leaf, 2015; Stuart, Cole, Bradshaw, & Leaf, 2011) . This approach is similar to the inverse probability weighting method, which is often used for nonexperimental studies (Mansournia & Altman, 2016) . We first estimated propensity score of RCT participation, p, which was defined as the conditional probability of an individual participating in the RCTs based on the eight variables described above.
The mean propensity score across 50 imputed data sets was used for TEDS-A to take into account the missing data. To calculate the propensity scores, we used a nonparametric random forests approach, using the "randomForest" (Liaw & Wiener, 2002) package in R (R Development Core Team, 2016) . Although the random forests approach has some advantages over a parametric approach such as a higher predictive accuracy and the ability to reduce extreme propensity scores (Strobl, Malley, & Tutz, 2009 ), we still encountered some outlying values for propensity scores and trial participation weights. In order to improve the performance of the propensity score-based weighting, we used weight trimming, also referred as truncation, in which we replaced extreme large values at the 95th percentile values following the method introduced in a study by Lee, Lessler, and Stuart (2011) . To assess generalizability of the findings of each RCT, we computed trial participation weights for each trial as (1 − p)/p. We conducted weighted regression analyses with the weights for each trial, (1 − p)/ p, using the STATA pweights command (version 13).
Third, we conducted unweighted and weighted pairwise metaanalyses of the four RCTs to estimate the overall treatment effect of cocaine dependence medications, which is a pooled treatment effect of four medications assessed through separately conducted RCTs as compared with placebo arms. The unweighted analyses estimated the sample treatment effects whereas the weighted analyses estimated population-generalized effects. For the binary outcome of retention, we estimated risk differences for treatment effects; whereas, for the continuous measure of days of abstinence in the past 30 days, we used linear regression models. Baseline variables in the trial samples were not adjusted, assuming that randomization was successful in each trial.
We estimated the pooled treatment effect with clustered standard errors at each trial level. In addition to comparing the statistical significance of the treatment effects from unweighted and weighted regression models, we also statistically compared the treatment effect sizes of unweighted and weighted models, using the STATA suest (seemingly unrelated estimation) command (Weesie, 1999) . Furthermore, to explore potential reasons for differences in sample and generalized treatment effects, we conducted a series of subgroup analyses in which we estimated treatment effects in subgroups that were overrepresented or underrepresented in the RCT samples compared with the target populations.
Fourth, to directly compare the effects of the medications, we conducted an unweighted and weighted network meta-analysis of the four RCTs to estimate the comparative treatment effects across the four medications. Past research has shown that statistical precision of estimated treatment effects from network meta-analyses is often better than that of estimated effects from pairwise comparisons in meta-analysis when the distributions of effect modifiers are balanced (Cipriani et al., 2013; Jansen & Naci, 2013; Salanti, 2012) . Network meta-analysis also allows for determination of relative rankings of multiple treatments (Salanti, Ades, & Ioannidis, 2011) . We fitted fixedeffect network meta-analysis models with the "gemtc" package in R (Dias, Welton, Caldwell, & Ades, 2010) . Table 1 from non-Hispanic White racial-ethnic groups, and those younger than 35 years old than the NSDUH; whereas, the trial samples had significantly higher proportions of married individuals than the NSDUH. Table 3 presents the results of the pairwise meta-analyses for the overall treatment effect on trial retention and abstinence. Risk ratios and mean differences (βs) from both unweighted and weighted regression models, respectively, are presented with the 95% confidence intervals. In addition, the results of comparisons of regression coefficients are presented in Table 3 .
| Comparison of characteristics of four CTN trials and target populations

| Pairwise meta-analysis
For retention, the overall population treatment effect was significantly larger for the analyses weighted by the NSDUH target population than the sample treatment effect (Table 3) . A risk ratio of 1.41 suggests that individuals receiving the active pharmaceutical agents have 1.41 times the likelihood of being retained in the study compared with those treated with placebo. In contrast, there was no statistically significant difference between the population-adjusted effect and the sample effect on self-reported abstinence (Table 3) . The results of subgroup analysis of treatment effects are presented in Table A2 . We found some consistent patterns in the directions of change in outcomes through weighting and by subgroup analysis. For example, the non-married individuals that were slightly underrepresented in the overall RCTs (p = .10) showed evidence of larger treatment effects on retention than the overrepresented group of married individuals. Weighting the RCT samples to resemble the NSDUH target population increased the weights for the subsample of non-married individuals that had larger treatment effect sizes, leading to a significantly larger treatment effect on retention after weighting with the NSDUH target population. Table 4 presents the results of network meta-analysis comparing the effect of the four medications on cocaine dependence. Risk ratios and mean differences (βs) from both unweighted and weighted regression models, respectively, are presented with the 95% confidence intervals. We also present the relative rankings of the treatments, computed as the probabilities of each treatment being the best among all the treatments in the network meta-analysis.
| Network meta-analysis
In the unweighted model for each medication, there was no significant treatment effect. Although it should be noted that the 95% confidence intervals for the estimated treatment effects for each medication overlapped with each other, Ondansetron was the most efficacious medication for retention, and Modafinil was the most efficacious medication for abstinence. Weighting altered the relative ranking of the treatments. For retention, weighting by TEDS-A and by NSDUH made the second most efficacious treatment, Modafinil, the third most efficacious. For abstinence, the least efficacious treatment, Reserpine, became the second most efficacious after weighting for both target populations. Moreover, Ondansetron was the second most efficacious treatment for retention before weighting; however, it became the second least efficacious treatment after weighting.
Data from subgroup analyses presented in Table A2 suggest treatment effect and the population treatment effect by applying the statistical weighing-based method to the 10 CTN studies, which assessed efficacy of SUD treatments. To our knowledge, the present study is the first to perform pairwise and network meta-analyses of multiple SUD treatments while using a weighting approach to consider generalizability of the findings to the target populations.
The findings from this study have implications for future metaanalytic studies of SUD treatments. As shown in this study, the overall treatment effect size and comparative effects changed when the deviations of each RCT sample from the target population were taken into account. Unlike the previous study by Susukida et al. (2017) Table A3 , there were statistically significant differences in the estimated propensity scores between each RCT and its target populations. The weighting-based method is more suitable to estimate the population treatment effect when the distributions of characteristics in RCTs overlap with those of the target populations. Third, the present study could only show suggestive evidence of treatment effect heterogeneity across subgroups of individuals in the clinical trial samples because the CTN studies did not originally intend to assess the treatment effect heterogeneity, and the subgroup analyses conducted here were not sufficiently powered. Lastly, the number of trials included in this study was limited, which likely limited the reliability of the network metaanalysis (Jansen et al., 2011) and our ability to conclude which medication is the most promising for treating cocaine dependence.
Limitations notwithstanding, the findings of this study provide insight into the generalizability of meta-analysis of cocaine depen- All the participants who had IV drug use in the treatment arm successfully retained in the study, and it was not possible to estimate a coefficient for interaction term.
b All the participants aged <35 years old in the treatment arm successfully retained in the study, and it was not possible to estimate a coefficient for interaction term.
c All the participants with less than 12 years of education in the control arm successfully retained in the study, and it was not possible to estimate a coefficient for interaction term.
d All the participants without full-time job in the control arm successfully retained in the study, and it was not possible to estimate a coefficient for interaction term.
e All the participants who had IV drug use successfully retained in the study, and it was not possible to calculate chi-squared statistics and to estimate a coefficient for interaction term.
f There was no observation of those who had no prior treatments.
g No female participants in the control arm successfully retained in the study, and it was not possible to estimate a coefficient for interaction term.
h All the participants who had IV drug use were in the treatment arm, and it was not possible to calculate chi-squared statistics and to estimate a coefficient for interaction term.
i There was only one observation in the control arm, and it was not possible to calculate t statistics.
j There was no observation in the control arm, and it was not possible to calculate t statistics and to estimate a coefficient for interaction term. Δp is difference between propensity scores of the RCT sample and the target population.
b Standardized Δp is computed as Δp divided by pooled standard deviation.
